The global ticagrelor market is witnessing substantial growth due to the increasing prevalence of cardiovascular diseases, growing aging population, and rising awareness regarding advanced antiplatelet therapies. According to recent market analysis, the global ticagrelor market size was valued at USD 1.99 billion in 2024 and is projected to grow from USD 2.17 billion in 2025 to USD 4.80 billion by 2033, registering a CAGR of 9.20% during the forecast period from 2025 to 2033.

Ticagrelor is widely used in the prevention and treatment of acute coronary syndrome (ACS), stroke, heart attacks, and other cardiovascular complications. The increasing incidence of heart-related disorders globally continues to create strong demand for effective antiplatelet therapies.

Understanding Ticagrelor and Its Medical Importance

Ticagrelor belongs to a class of organic compounds known as triazolopyrimidines and functions as an antiplatelet medication. The drug works by preventing platelet aggregation and reducing blood clot formation, thereby lowering the risk of serious cardiovascular events.

Ticagrelor binds to the P2Y12 receptor and inhibits adenosine diphosphate (ADP) signaling, preventing platelets from becoming activated. This mechanism significantly reduces the likelihood of blood clot development in patients with cardiovascular conditions.

The medication, commonly marketed under the brand name Brilinta, is primarily used for treating acute coronary syndrome and preventing recurring cardiovascular complications.

Increasing Cardiovascular Disorders Fueling Market Growth

The growing global burden of cardiovascular diseases remains one of the primary factors driving the ticagrelor market. Cardiovascular disorders, including heart attacks, strokes, and coronary artery diseases, continue to be among the leading causes of death worldwide.

According to data from the American Heart Association, approximately 31% of deaths in the United States were linked to cardiovascular disorders. Rising cases of hypertension, obesity, diabetes, smoking, high cholesterol, and unhealthy lifestyles are significantly increasing the number of patients requiring antiplatelet therapies.

Ticagrelor, especially when combined with aspirin, has shown improved effectiveness in reducing vascular deaths and myocardial infarctions compared to conventional therapies such as clopidogrel combined with aspirin. This clinical advantage is contributing to the growing adoption of ticagrelor-based treatment protocols globally.

Growing Geriatric Population Supporting Market Expansion

The rapidly increasing elderly population worldwide is another major factor contributing to market growth. Older adults are more vulnerable to chronic conditions such as cardiovascular diseases, arthritis, kidney disorders, and metabolic illnesses, increasing the need for long-term cardiovascular treatments.

According to the United Nations, the global population aged 60 years and above is expected to nearly double by 2050. The aging population in North America, Europe, and Asia-Pacific is creating substantial demand for cardiovascular medications, including ticagrelor.

As elderly patients are more prone to acute coronary syndrome, stroke, and heart surgeries, healthcare providers are increasingly prescribing antiplatelet therapies to reduce the risk of severe cardiovascular events.

Expanding Applications Creating New Market Opportunities

The growing exploration of ticagrelor for additional therapeutic applications is opening new opportunities for market growth. Pharmaceutical companies are actively conducting research to evaluate the drug’s effectiveness in treating conditions beyond acute coronary syndrome.

AstraZeneca is currently exploring the use of ticagrelor in the prevention of acute ischemic stroke, transient ischemic attacks, and vaso-occlusive crises in pediatric sickle cell disease patients.

The expansion of ticagrelor into new treatment areas is expected to broaden its patient base and create additional revenue opportunities for pharmaceutical manufacturers during the forecast period.

Bleeding Risks Remain a Major Challenge

Despite its clinical benefits, ticagrelor therapy is associated with significant bleeding risks, which remain a key challenge for market growth. The drug may increase the risk of severe bleeding complications, including internal bleeding, bruising, and prolonged bleeding episodes.

In some cases, patients may require blood transfusions or surgical intervention to manage bleeding complications. Common side effects associated with ticagrelor include breathlessness, headaches, nausea, dizziness, and nosebleeds.

These safety concerns may limit the use of ticagrelor among high-risk patients and require careful monitoring by healthcare professionals.

Americas Dominate the Global Ticagrelor Market

The Americas region currently dominates the global ticagrelor market and is expected to maintain strong growth throughout the forecast period. Rising healthcare expenditure, advanced healthcare infrastructure, increasing obesity rates, and growing cardiovascular disease prevalence are supporting regional market expansion.

The United States remains a major contributor to market growth due to its large patient population suffering from cardiovascular disorders. According to the American Heart Association, cardiovascular diseases caused one in every three deaths in the U.S. in 2014.

The increasing focus on early diagnosis, advanced treatment options, and preventive cardiovascular care is expected to further strengthen the market in North America.

Europe and Asia-Pacific Witness Significant Growth

Europe is projected to witness strong market growth due to rising cardiovascular disease cases, increasing healthcare spending, and growing research on advanced antiplatelet therapies. Improved healthcare infrastructure and access to modern cardiovascular treatments are also supporting market expansion across the region.

Meanwhile, the Asia-Pacific region is expected to experience substantial growth due to rising per capita income, improving healthcare systems, and increasing awareness about cardiovascular disease prevention. Countries such as China, India, and Australia are emerging as important growth markets for ticagrelor therapies.

The growing elderly population and rising incidence of metabolic disorders in Asia-Pacific are expected to further accelerate market demand during the forecast period.

90 mg Dosage Segment Leads the Market

Based on dosage, the 90 mg ticagrelor segment accounted for the largest market share and is expected to maintain its dominance throughout the forecast period. The strong demand for the 90 mg dosage is attributed to its high efficacy and widespread clinical recommendation for acute coronary syndrome treatment.

The 90 mg formulation is approved in more than 100 countries and is recommended as an initial treatment option for acute coronary syndrome and myocardial infarction during the first year of therapy.

Meanwhile, the 60 mg dosage is commonly prescribed for long-term prevention of cardiovascular events in patients with a history of myocardial infarction.

Hospitals and Clinics Remain Key End Users

Hospitals and clinics dominate the ticagrelor market due to the increasing need for diagnosis and treatment of acute coronary syndrome and heart surgeries. Advanced healthcare infrastructure and access to specialized cardiovascular treatment facilities are contributing to the strong demand within hospital settings.

The oral route of administration also remains the preferred treatment method because of its convenience and high patient compliance.

Key Companies Operating in the Market

Leading pharmaceutical companies operating in the ticagrelor market include:

• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Eli Lilly
• Sun Pharmaceutical Industries Ltd

These companies are actively investing in clinical trials, product development, and strategic partnerships to strengthen their cardiovascular treatment portfolios.

Read Full ticagrelor market Report- https://straitsresearch.com/report/ticagrelor-market